Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Encephalomyelopathy  (2)
  • Hyperphenylalaninaemia  (1)
  • MRI of the brain  (1)
  • 1
    ISSN: 1433-0474
    Keywords: Schlüsselwörter Erbkrankheit ; Ornithintranscarbamylase ; Mutation ; Neurologischer Befund ; Selektives Screening ; MRT ; Key words Inborn error ; Ornithine transcarbamylase ; Mutation ; Neurological findings ; Selective screening ; MRI of the brain
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary X-linked inherited OTC-deficiency is the most frequent inborn error of urea synthesis. Molecular heterogeneity is shown by more than 50 mutations at the OTC-gene locus reflecting a broad clinical spectrum. We report on a normally developed 16 months old girl who never had coma or lethargy but presented with neurological symptoms such as minor ataxia and increased muscular tonus and discrete athetoidal movements of the upper extremities. EEG showed only minor abnormalities, in the MRI of the brain enhanced, frontal and occipital periventricular signal intensities were detectable. Biochemical findings were typical for OTC-deficiency with a moderate hyperammonemia (up to 332 μmol/l), normal basic amino acids in plasma and a high excretion of orotic acid and uracil in urine (735 and 370 mmol/mol creatinine resp.). DNA analysis showed a novel G 〉 T mutation at the intron1/exon1 boundary, which apparently led to an abnormal splicing of the DNA. After introducing a dietary and medical treatment, neurological symptoms disappeared, blood ammonia became normal, MRI changes almost completely disappeared 3 months after therapy was started. Discussion: This case illustrates that a selective screening for inborn errors of metabolism should also be performed in patients with minor neurological symptoms.
    Notes: Zusammenfassung Der X-chromosomal vererbte OTC-Defekt ist die häufigste angeborene Harnstoffzykluserkrankung. Die auf molekularer Ebene nachgewiesene Heterogenität mit mehr als 50 Mutationen im OTC-Gen ist die Basis für klinisch sehr unterschiedliche Verläufe. Wir berichten über ein 16 Monate altes, normal entwickeltes Mädchen, das lediglich durch diskrete neurologische Symptome auffiel. Lethargie oder ein Koma waren nie beobachtet worden. Das ansonsten normal entwickelte Kind zeigte eine geringe, stammbetonte Ataxie, ein leicht athetoides Bewegungsmuster und vermehrte Strecktendenz in den Armen. Das EEG zeigte nur geringe Zeichen einer Allgemeinstörung, im Kernspintomogramm des Schädels fanden sich massive, periventrikuläre Signalanreicherungen okzipital und frontal. Die biochemischen Befunde waren typisch für einen OTC-Defekt mit einer leichten Hyperammonämie bis 332 μmol/l und einer stark erhöhten Orotsäure- und Uracilausscheidung (735 bzw. 370 mmol/mol Kreatinin). Molekulargenetisch zeigte sich im OTC-Gen eine bislang nicht beschriebene G 〉 T Mutation an der Intron1-Exon1-Grenze, die offensichtlich zu einem Splice-site-Defekt führt. Nach diätetischer und medikamentöser Behandlung war das Kind klinisch unauffällig, das Ammoniak im Blut normalisierte sich. Drei Monate nach Behandlungsbeginn waren die MRT-Signalanreicherungen fast vollständig zurückgebildet. Diskussion: Der Fall zeigt, daß ein selektives Screening auf angeborene Stoffwechselerkrankungen auch bei sehr uncharakteristischen, neurologischen Symptomen notwendig ist.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1076
    Keywords: Methylmalonic aciduria ; Vitamin B12 ; GABA ; Cerebrospinal fluid ; Encephalomyelopathy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We report on two siblings, a girl of 7 years and a boy of 2 years, who presented in infancy with hypotonia, athetoid movements, myopathy and severe developmental delay. The progressive clinical course was characterized by ophthalmoplegia, pyramidal tract signs, loss of visual contanct and failure to thrive. The older sister died at the age of 7 years. The younger brother followed an almost identical clinical course. MRI of the brain revealed bilateral hypodensities and atrophy of the putamen. Neurophysiological investigations were consistent with peripheral neuropathy. Investigations for neurometabolic disorders in urine, plasma and CSF of both patients revealed a consistent increase of methylmalonic acid in urine, plasma and CSF as well as borderline low free GABA in CSF. Except for an inconstant elevation of lactate in the boy, metabolic acidosis, hypoglycaemia, episodic ketoacidosis, or hyperammonaemia, the usual concomitants of organoacidopathies, were absent in both children. Homocystinuria was excluded. Methylmalonic aciduria did not respond to antibiotic treatment, vitamin B12 therapy nor dietary protein restriction. Incorporation of [14C]propionate into protein in cultured fibroblasts was pathologically but inconsistently decreased. Both patients' cell lines showed only minimal response to hydroxocobalamin and normal methylmalonyl-CoA mutase activity. Conclusion Even though the definitive undorlying enzymatic defect in this sibship remains obscure our results suggest a new genetic disorder. This report illustrates that hitherto undescribed metabolic disorders remain to be elucidated even in long investigated areas of intermediary metabolism such as methylmalonic aciduria.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-1076
    Keywords: Key words Phenylketonuria ; Hyperphenylalaninaemia ; Phenylalanine levels ; Treatment recommendations
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Treatment of hyperphenylalaninaemias due to phenylalanine hydroxylase deficiency with a low phenylalanine (Phe) diet is highly successful in preventing neurological impairment and mental retardation. There is consensus that, for an optimal outcome, treatment should start as early as possible, and that strict blood Phe level control is of primary importance during the first years of life, but for adolescent and adult patients international treatment recommendations show a great variability. A working party of the German Working Group for Metabolic Diseases has evaluated research results on IQ data, speech development, behavioural problems, educational progress, neuropsychological results, electroencephalography, magnetic resonance imaging, and clinical neurology. Based on the actual knowledge, recommendations were formulated with regard to indication of treatment, differential diagnosis, and Phe level control during different age periods. The development of the early-and-strictly-treated patient in middle and late adulthood still remains to be investigated. Therefore, the recommendations should be regarded as provisional and subject to future research. Efficient treatment of phenylketonuria has to go beyond recommendations for blood Phe level control and must include adequate dietary training, medical as well as psychological counselling of the patient and his family, and a protocol for monitoring outcome. Conclusions Early-and-strictly-treated patients with phenylketonuria show an almost normal development. During the first 10 years treatment should aim at blood Phenyl-alanine levels between 40 and 240 μmol/L. After the age of 10, blood phenylalanine level control can be gradually relaxed. For reasons of possible unknown late sequelae, all patients should be followed up life-long.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-1076
    Keywords: Key words Methylmalonic ; aciduria ; Vitamin B12 ; GABA ; Cerebrospinal fluid ; Encephalomyelopathy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We report on two siblings, a girl of 7 years and a boy of 2 years, who presented in infancy with hypotonia, athetoid movements, myopathy and severe developmental delay. The progressive clinical course was characterized by ophthalmoplegia, pyramidal tract signs, loss of visual contact and failure to thrive. The older sister died at the age of 7 years. The younger brother followed an almost identical clinical course. MRI of the brain revealed bilateral hypodensities and atrophy of the putamen. Neurophysiological investigations were consistent with peripheral neuropathy. Investigations for neurometabolic disorders in urine, plasma and CSF of both patients revealed a consistent increase of methylmalonic acid in urine, plasma and CSF as well as borderline low free GABA in CSF. Except for an inconstant elevation of lactate in the boy, metabolic acidosis, hypoglycaemia, episodic ketoacidosis, or hyperammonaemia, the usual concomitants of organoacidopathies, were absent in both children. Homocystinuria was excluded. Methylmalonic aciduria did not respond to antibiotic treatment, vitamin B12 therapy nor dietary protein restriction. Incorporation of [14C]propionate into protein in cultured fibroblasts was pathologically but inconsistently decreased. Both patients’ cell lines showed only minimal response to hydroxocobalamin and normal methylmalonyl-CoA mutase activity. Conclusion Even though the definitive underlying enzymatic defect in this sibship remains obscure our results suggest a new genetic disorder. This report illustrates that hitherto undescribed metabolic disorders remain to be elucidated even in long investigated areas of intermediary metabolism such as methylmalonic aciduria.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...